antihyperlipidemic effects of pleurotus ostreatus (oyster mushrooms) in hiv-infected individuals taking antiretroviral therapyantihyperlipidemic影响平菇(牡蛎蘑菇)在感染艾滋病毒的人服用抗逆转录病毒治疗.pdfVIP

Abrams et al. BMC Complementary and Alternative Medicine 2011, 11:60 /1472-6882/11/60 RESEARCH ARTICLE Open Access Antihyperlipidemic effects of Pleurotus ostreatus (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy 1* 2 3 4 5 6 Donald I Abrams , Paul Couey , Starley B Shade , Mary Ellen Kelly , Nnemdi Kamanu-Elias and Paul Stamets Abstract Background: Antiretroviral treatment (ART) regimens in HIV patients commonly cause significant lipid elevations, including increases in both triglycerides and cholesterol. Standard treatments for hypercholesterolemia include the HMG CoA reductase inhibitors, or “statins.” Because many ART agents and statins share a common metabolic pathway that uses the cytochrome P450 enzyme system, coadministration of ART with statins could increase statin plasma levels significantly. The oyster mushroom, Pleurotus ostreatus, has been shown in animal models to decrease lipid levels - a finding that has been supported by preliminary data in a small human trial. Methods: To assess the safety and efficacy of P. ostreatus in patients with HIV and ART-induced hyperlipidemia, a single-arm, open-label, proof-of-concept study of 8 weeks’ duration with a target enrollment of 20 subjects was conducted. Study patients with ART-induced elevated non-HDL cholesterol levels ( 160 mg/dL) were enrolled. Participants received packets of freeze-dried P. ostreatus (15 gm/day) to be administered orally for the 8 week trial period. Lipid levels were drawn every two weeks to assess efficacy. Safety assessments included self-reported incidence of muscle aches and measurement of liver and muscle enzymes. Mean within-person change in lipid leve